Hepatitis C News

Screening mothers who delivered infants via cesarean section, or who had undergone other surgical procedures, could reduce vertical transmission of HCV, according to findings presented by Mohamed Alboraie at United European Gastroenterology Week in Vienna.

Amid an epidemic of opioid abuse in the United States that has contributed to a 150% rise in acute HCV infections in recent years and is blamed for nearly 1 in 10 new HIV infections, there is evidence that people who inject drugs are visiting syringe service programs at a higher rate than they were a decade ago, according to a new report by the CDC.

BOSTON — A small group of patients with hepatitis C virus and hepatitis B virus coinfection experienced spontaneous HBV reactivation after successful direct-acting antiviral therapy, according to findings presented at The Liver Meeting 2016.

BOSTON — A novel pangenotypic protease inhibitor, voxilaprevir, yielded encouraging outcomes when administered with Epclusa, regardless of HCV genotype or cirrhosis status, but remained non-inferior to the combination direct-acting antiviral, according to findings presented at The Liver Meeting 2016.

Researchers found through long-term follow-up that patients with hepatitis C virus infection who achieved sustained virologic response after interferon-based therapy were still at risk for hepatocellular carcinoma, more specifically older patients and those with cirrhosis.

BOSTON — In this exclusive video at The Liver Meeting, Andrew M. Hill, PhD, discusses data from a new study that show the price of a direct-acting antiviral generic regimen could be as low as $80 in the U.S. to cure hepatitis C virus infection in one patient.

Harvoni was the single drug with the highest total spending by Medicaid in 2015, surpassing Abilify — treatment for depression and other illnesses — CMS announced on its official blog.

Kidney transplant recipients with hepatitis C virus genotype 1 or 4 were safely and effectively treated with Harvoni for up to 24 weeks, according to research published in Annals of Internal Medicine.

BOSTON — In this exclusive video from The Liver Meeting, Stefan Zeuzem, MD, chief of the department of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany, discusses results of the ENDURANCE-1 clinical trial where a treatment regimen of glecaprevir/pibrentasvir (G/P) yielded high sustained virologic response rates in patients with hepatitis C genotype 1 after 8 weeks of treatment.

BOSTON — A novel regimen demonstrated pangenotypic activity and safety in patients with hepatitis C infection with advanced chronic kidney disease, according to findings presented during the Late Breaker session at The Liver Meeting 2016.